## Pulmonary permeability in primary ciliary dyskinesia

S. Groth, M. Pedersen

Pulmonary permeability in primary ciliary dyskinesia. S. Groth, M. Pedersen. ABSTRACT: Pulmonary clearance (Pcl) of aerosolized 99mTc-DTPA was studied in fourteen patients with primary cliiary dyskinesia (PCD), (median age 23.5 yrs, range 12-44 yrs) and nine normal individuals (median age 23 yrs, range 18-27 yrs). All had never smoked. Regional Pcl was studied for arbitrarily defined central and peripheral regions of the lung using a gamma camera method, whilst total Pcl was studied by a plasma sample method. The patients with PCD had significantly reduced total Pcl compared to the normal individuals (p<0.05) and also significantly lower total lung capacity (TLC), vital capacity (VC), forced expiratory volume in one second (FEV<sub>1</sub>), and FEV<sub>1</sub>/VC values (p<0.05). There was no correlation between Pcl and FEV<sub>1</sub>/VC. It is concluded that the reduced Pcl in the PCD patients may be associated with their small lung volumes. In addition, reduced bronchial clearance of surfactant in PCD may be associated with an increased alveolar lining fluid volume and/or an impaired movement of ""Tc-DTPA along the alveolar septa to the bronchoalveolar junction, where the epithelium may be more specialized for absorption.

Eur Respir J., 1989, 2, 64-70.

Since 1977 [1] it has been customary to assess pulmonary permeability by measuring pulmonary clearance rate (Pcl) of inhaled nebulized 99mTc-DTPA (diethylenetriamine-penta-acetic acid). Recently it has been suggested that the surfactant lining of the alveoli is of importance for maintaining an intact epithelial permeability [2]. In the transition between the airways and the alveoli there is a functional continuity between the mucous layer of the airways and the surfactant lining of the alveoli. In normal individuals a substantial part of the alveolar surfactant is removed via the airways by mucociliary clearance. In patients with primary ciliary dyskinesia (PCD) the primary pulmonary defect is exclusively located to ciliated airways [3]. Any parenchymal involvement in these patients is, therefore, likely to be closely related to the diseased mucociliary clearance.

The aim of this study was to examine pulmonary parenchymal involvement in PCD as measured by Pcl of <sup>99m</sup>Tc-DTPA. Therefore, we compared Pcl of fourteen patients with PCD with that of nine normals. The results were related to the presence of obstructive and restrictive lung disease as evidenced by conventional spirometry and the pattern of ventilation as measured by <sup>99m</sup>Tc-DTPA ventilation scintigraphy. Pulmonary permeability was measured by two methods: 1) a plasma sample method [4] that estimates an average Pcl for all the <sup>99m</sup>Tc-DTPA that is accessible to pulmonary clearance; and 2) a gamma camera method that estimates regional and whole lung clearance from the Dept of Clinical Physiology and Nuclear Medicine and Dept of Pediatrics, Rigshospitalet, Copenhagen, Denmark.

Correspondence: S. Groth, Dept of Clinical Physiology and Nuclear Medicine, Rigshospitalet, 49 Strandboulevarden, DK-2100 Copenhagen Ø, Denmark.

Keywords: Alveolar epithelial permeability; lung injury; primary ciliary dyskinesia; <sup>99m</sup>Tc-DTPA.

Received: September 3, 1988.

initial slope of the detected decline in radioactivity, thereby predominantly providing information about the Pcl of the <sup>99m</sup>Tc-DTPA that is accessible to immediate transport across the alveolar-capillary barrier.

#### Individuals and methods

Fourteen patients with primary ciliary dyskinesia (median age 23.5 yrs, range 12–44 yrs), and nine normal individuals (median age 23.0 yrs, range 18–27 yrs) participated in the study. None of the individuals had ever smoked. Informed consent was obtained in each case and if younger than 18 yrs, from their parents also. The diagnosis of PCD was based on history, a saccharine clearance test of the nose [5], and *in vitro* microphoto-oscillographic measurement of motility of nasal cilia [6] and transmission electron microscopy of the cilia [7]. The study was approved by the local Ethical Committee.

#### Lung volume, flow variables and diffusion capacity

Spirometry was performed with computerized Jaeger equipment (Transferscreen<sup>®</sup>). The forced expiratory volume in one second (FEV<sub>1</sub>), peak expiratory flow rate (PEF), and maximum expiratory flow rate at 50% of the forced vital capacity (MEF<sub>50</sub>) were read from the largest of three flow-volume curves. Vital capacity (VC)

was measured as the inspiratory vital capacity, the largest of three attempts being used. Total lung capacity (TLC) was measured by a single-breath heliumdilution method. Residual volume (RV) was calculated as RV=TLC-VC. Diffusion capacity was measured as the transfer factor of the lungs for carbon monoxide (TLCo) by a single-breath method [8]. The results were calculated for predicted values for adults [8] or for children if the individual was younger than 18 yrs old [3].

#### Determination of pulmonary clearance of 99mTc-DTPA

Preparation of  $^{99m}Tc-DTPA$ . Sodium pertechnetate  $(^{99m}TcO_4)$  was eluted in isotonic saline from a  $^{99}Mo/$ <sup>99m</sup>Tc generator (IRE). The  $^{99m}Tc$  was chelated to DTPA (DuPont) introducing 700 MBq  $^{99m}TcO_4$  into a kit containing 10 mg of DTPA in a maximum volume of 5 ml isotonic saline. The  $^{99m}Tc$ -DTPA (molecular weight 492 daltons) was made 1 h before use and stored in a nitrogen atmosphere. The binding of  $^{99m}Tc$ -DTPA was found to be >97% complete by chromatography, where the separation of  $^{99m}Tc$ -DTPA and  $^{99m}TcO_4^-$  was achieved with acetone on alufoil cellulose. The subsequent ultrasonic nebulization did not cause chemical breakdown of the  $^{99m}Tc$ -DTPA.

Aerosol generation and administration. The aerosol was generated in an ultrasound nebulizer (DeVilbiss 35B) containing the 700 MBq 99mTc-DTPA. It was inhaled from the nebulizer and on its way to the mouth it passed a 10 l container and a 1 m long hose to permit settling of larger droplets. At the mouth the aerosol particles had a mass diameter of 0.5-2.1 µm (98% <1.5 µm). A T-valve ensured that the expired air could be collected in a trap. Individuals inhaled the aerosol at slightly deeper inspirations than tidal volume. Each inspiration was slow and was followed by a 3 s pause (breath held) before expiration. The inhalation was made with the subject in the sitting position. The aerosol was administered for a maximum of 3 min, yielding a maximum count-rate of 120,000 counts per min over the entire lung field. The background count-rate was 500-1000 counts per min.

# Determination of Pcl of 99mTc-DTPA by the gamma camera method

Data acquisition. Immediately after inhalation of the aerosol, the patient was seated, with back against an Anger-type scintillation gamma carnera (LFOV, Searle Radiographic Inc.) having a standard field-of-view size crystal and a parallel 140 KeV collimator. Dynamic acquisition of the detected lung field radioactivity was made for 10 min on a computer (MED II, Nuclear Data). The acquisition was framed at 20 s intervals. During the acquisition, ventilation scintigrams were made on Polaroid films.

Data processing. The acquired data were processed to

display initial distribution of the activity of <sup>99m</sup>Tc-DTPA. Regions of interest were created by fitting a rectangle form as closely as possible over the lung. The rectangles were divided into 3x6 units (fig. 1) and used to arbitrarily define the lung as being composed of a central and lateral part. Initial central and peripheral deposition of the activity was calculated (%) by pooling the initial count-rate of the respective parts of the two lungs.




Fig. 1. – Regions which were analysed by the external detection method. C: central parts; P: peripheral parts.

To determine Pcl, a monoexponential fit was applied to the time-activity curve for the whole lung and for the central and peripheral parts separately. The background and the physical decay of <sup>99m</sup>Tc were corrected for. Pcl was described by the time constant of the monoexponential function (K), which is a commonly used index for presentation of the results of the method. The reciprocal value, 1/K, however, is the mean transit time for the transport of <sup>99m</sup>Tc-DTPA across the alveolar capillary membrane, as estimated from the <sup>99m</sup>Tc-DTPA that was accessible for transport during the first 10 min after the inhalation. It provided the mathematical basis for comparing the results of the plasma sample method and the gamma camera method.

#### Determination of Pcl by the plasma sample method

General procedure. At 30 min after the end of inhalation, a bolus injection of a weighed amount of 3 MBq <sup>51</sup>Cr-EDTA (ethylene diamine tetra-acetic acid) was injected intravenously. Standards were produced.

Five ml plasma samples were drawn from an indwelling needle before and 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 150, 180, 200, 220 and 240 min after the end of inhalation. The radioactivity in plasma samples was used to determine the plasma time activity curve for <sup>99m</sup>Tc-DTPA following the inhalation (C(t)DTPA) and for <sup>51</sup>Cr-EDTA following the *i.v.* injection (C(t)EDTA.

Samples were counted in a well-scintillator for the

two gamma energies separately. Standard counting error: 1.00%.

Calculations. A two compartment model was applied [4] to calculate Pcl from all the  $^{99w}$ Tc-DTPA that was accessible for transport across the alveolar capillary membrane. The model uses the fact that the mean transit time (t) for compartments in series is the sum of the t for the transport through each of the compartments [11].

Mean transit time for the transport of 99mTc-DTPA through the lungs ( $\bar{t}(L)$ ) was calculated as:

$$\overline{t}$$
 (L) =  $\overline{t}$  (L+ECV) DTPA- $\overline{t}$  (ECV) EDTA

where the  $\bar{t}(L+ECV)$  is the  $\bar{t}$  for the transport of <sup>99m</sup>Tc-DTPA from the lungs *via* the extracellular volume (ECV) to the kidney, which is the only organ of elimination, and  $\bar{t}(ECV)EDTA$  is the  $\bar{t}$  for the transport of <sup>51</sup>Cr-EDTA through the ECV to the kidney.  $\bar{t}(L+ECV)DTPA$  and  $\bar{t}(ECV)EDTA$  werecalculated from C(t)DTPA and C(t)EDTA from the general formula:

$$t = \int tC(t)dt / \int C(t)dt$$

where C(t) is the t-a curve for the tracer in question.

<sup>51</sup>Cr-EDTA plasma clearance was calculated from C(t)EDTA as an index of glomerular filtration rate according to the two compartment mamillary model of SAPIRSTEIN et al. [12].

The <sup>51</sup>Cr-EDTA distribution space is an index of ECV and was calculated from C(t)EDTA from the same two compartment model of Sapirstein.

Statistical analysis. Results were compared by means of Student's t test for paired and unpaired data.

#### Results

The PCD patients had systematically lower TCL, VC, FEV<sub>1</sub> and FEV<sub>1</sub>/VC values (% predicted) than the normal individuals (p<0.05, table 1). Four of the patients with PCD (nos. 1, 2, 7 and 14) had slight to moderate obstructive lung disease (FEV,/FVC <75%),

Table 1. - Results of the measurements of lung volumes and diffusing capacity

| Normal                     | T    | LC    | R    | ev    | v    | С     | FE   | V <sub>1</sub> | TLCo<br>mmol·                      | D     | RV/TLC | FEV,<br>VC |
|----------------------------|------|-------|------|-------|------|-------|------|----------------|------------------------------------|-------|--------|------------|
| individuals                | l    | %pred | l    | %pred | 1    | %pred | 1    | %pred          | s <sup>-1</sup> ·kPa <sup>-1</sup> | %prec | 1 %    | %          |
| 1                          | 6.85 | 109   | 1.39 | 99    | 5.46 | 113   | 4.10 | 95             | 0.195                              | 103   | 20     | 75         |
| 2<br>3<br>4                | 7.16 | 94    | 1.99 | 114   | 5.17 | 89    | 4.40 | 86             | 0.199                              | 87    | 28     | 85         |
| 3                          | 9.05 | 122   | 3.58 | 207   | 5.47 | 99    | 4.60 | 95             | 0.189                              | 87    | 40     | 84         |
| 4                          | 6.20 | 126   | 2.00 | 137   | 4.20 | 120   | 3.10 | 97             | 0.148                              | 106   | 32     | 74         |
| 5                          | 5.80 | 113   | 2.04 | 139   | 3.76 | 102   | 3.50 | 105            | 0.131                              | 89    | 35     | 93         |
| 6                          | 6.85 | 98    | 1.39 | 84    | 5.46 | 107   | 4.10 | 92             | 0.195                              | 98    | 20     | 75         |
| 7                          | 8.59 | 110   | 2.52 | 132   | 6.07 | 108   | 5.30 | 110            | 0.200                              | 91    | 29     | 87         |
| 6<br>7<br>8                | 6.76 | 104   | 1.64 | 109   | 5.12 | 106   | 4.40 | 103            | 0.202                              | 107   | 24     | 86         |
| 9                          | 7.36 | 103   | 2.13 | 107   | 5.23 | 85    | 4.70 | 88             | 0.208                              | 85    | 29     | 89         |
| x                          | 7.18 | 108   | 2.08 | 125   | 5.10 | 103   | 4.24 | 97             | 0.185                              | 95    | 7      | 83         |
| SD                         | 1.05 | 10    | 0.67 | 36    | 0.70 | 11    | 0.65 | 8              | 0.027                              | 9     |        | 7          |
| PCD Patients               |      |       |      |       |      |       |      |                |                                    |       |        |            |
| 1                          | 4.16 | 92    | 0.95 | 79    | 3.18 | 96    | 2.00 | 65             | 0.137                              | 104   | 24     | 63         |
| 2<br>3<br>4<br>5<br>6<br>7 | 5.52 | 94    | 1.69 | 112   | 3.83 | 94    | 2.10 | 62             | 0.135                              | 89    | 31     | 55         |
| 3                          | 4.06 | 98    | 1.00 | 96    | 3.06 | 91    | 2.20 | 71             | 0.145                              | 108   | 25     | 72         |
| 4                          | 5.39 | 107   | 1.26 | 116   | 4.13 | 104   | 3.30 | 94             | 0.139                              | 92    | 23     | 80         |
| 5                          | 3.68 | 65    | 1.54 | 87    | 2.14 | 59    | 0.75 | 24             | 0.095                              | 66    | 42     | 36         |
| 6                          | 4.37 | 88    | 1.44 | 152   | 2.93 | 75    | 1.55 | 48             | 0.159                              | 154   | 33     | 53         |
| 7                          | 7.69 | 99    | 1.98 | 110   | 5.71 | 97    | 3.90 | 76             | 0.250                              | 107   | 26     | 68         |
| 8                          | 2.86 | 84    | 0.80 | 114   | 2.02 | 72    | 1.80 | 78             | 0.077                              | 73    | 28     | 89         |
| 9                          | 5.85 | 101   | 1.40 | 102   | 4.45 | 113   | 3.25 | 94             | 0.153                              | 97    | 24     | 73         |
| 10                         | 3.63 | 82    | 1.24 | 131   | 2.39 | 68    | 1.50 | 49             | 0.106                              | 78    | 34     | 63         |
| 11                         | 4.23 | 89    | 1.24 | 91    | 2.99 | 72    | 1.40 | 47             | 0.121                              | 92    | 29     | 47         |
| 12                         | 3.69 | 83    | 1.10 | 116   | 2.59 | 74    | 2.05 | 66             | 0.112                              | 83    | 30     | 79         |
| 13                         | 4.45 | 90    | 1.41 | 99    | 3.04 | 87    | 2.45 | 79             | 0.123                              | 89    | 32     | 81         |
| 14                         | 4.35 | 94    | 1.12 | 83    | 3.23 | 101   | 1.90 | 66             | 0.131                              | 104   | 26     | 59         |
| x                          | 4.57 | 90    | 1.30 | 106   | 3.26 | 86    | 2.15 | 66             | 0.135                              | 95    | 29     | 66         |
| SD                         | 1.21 | 10    | 0.31 | 20    | 0.99 | 16    | 0.84 | 19             | 0.040                              | 21    | 5      | 15         |

TLC: Total lung capacity; RV: residual volume; VC: vital capacity; FEV<sub>1</sub>: forced expiratory volume in one second; TLCO: transfer factor of lungs for carbon monoxide; PCD: primary ciliary dyskinesia.

66

two (nos. 8 and 12) had a restrictive disease (TLC or VC <75% predicted) whilst four (nos. 5, 6, 10 and 11) had signs of combined disease. One of the patients (no. 5) also had reduced values [9] of the transfer factor. The individuals of the control group had normal spirometry and diffusing capacity.

All normal individuals, but only three of the PCD patients (nos. 4, 7 and 8) had normal ventilation scintigrams (fig. 2), *i.e.*, there were no ventilation defects and the distribution of the retained radioactivity was homogenous. Six of the patients (nos. 1, 2, 3, 9, 12 and 13) had slightly irregular distribution. Two of these (nos. 1 and 12) also had ventilation defects. Four of the patients (nos. 5, 6, 10 and 11) had severe irregular distribution with a spotty appearance and several ventilation defects. These were the patients that also had a combined restrictive and obstructive lung disease.




Fig. 2. - Ventilation scintigrams of the 14 (1-14) patients with primary ciliary dyskinesia.

The results of the quantitative analysis of the aerosol deposition in the lungs are given in table 2. The amount of central deposition of the aerosol was greater in the patients with PCD than in the controls (p<0.05). In both groups, <sup>99m</sup>Tc-DTPA tended to be cleared faster from the peripheral parts of the lungs, than from the central parts, but it was only within the group of normal individuals that significance was reached (p<0.05).

The results of the overall Pcl as measured by the plasma sample method are shown in table 3. The presumptions for using the plasma sample method were considered fulfilled, since all of the individuals in the study appeared to be clinically in a steady state and without ocdema. Moreover, none of the individuals had excessively large ECV volumes as evidenced by the distribution space of <sup>51</sup>Cr-EDTA. Surprisingly, one of the patients with PCD (the oldest, patient no. 2) had reduced <sup>51</sup>Cr-EDTA clearance value, probably due to previous treatments with gentamicin.

The results of the plasma sample method showed that the pulmonary epithelial permeability was significantly smaller (p<0.05) in the PCD group than in the group of controls. The results of determining Pcl by the plasma sample method provide information about the mean transit time for all the  $^{99m}$ Tc-DTPA that was accessible for transport across the alveolar capillary membrane. This was in line with the trend of the Pcl (whole lung, table 2), as calculated by the external detection method, which provides information about the  $^{99m}$ Tc-DTPA that was accessible for immediate transport.

In figures 3 and 4, the values for individual transport time,  $\bar{t}(L)$ , have been compared to the FEV<sub>1</sub>/FVC and TLCO values, respectively. In none of the groups, however, was the pulmonary permeability significantly correlated to the presence of airflow limitation or decreased diffusion capacity.

|             | Aerosol dep            | osition %           | K-values x 10 <sup>3</sup> min <sup>-1</sup> |                        |                     |  |  |  |
|-------------|------------------------|---------------------|--|------------------------|---------------------|--|--|--|
|             | Peripheral<br>part (P) | Central<br>part (C) | Whole<br>lung                                | Peripheral<br>part (P) | Central<br>part (C) |  |  |  |
| Normal      | 40.3                   | 59.7                | 8.4  | 9.7                    | 7.4                 |  |  |  |
| individuals | (±8.6)                 | (±8.6)              | (±3.4)                                       | (±4.1)                 | (±3.6)              |  |  |  |
| PCD         | 27.5                   | 72.5                | 6.2  | 7.6                    | 5.8                 |  |  |  |
| patients    | (±5.5)                 | (±5.5)              | (±3.3)                                       | (±4.1)                 | (±3.2)              |  |  |  |

Table 2. – Results of the quantitative analyses of the deposition of the <sup>99m</sup>Tc-DTPA aerosols in regions of interest and of the determination of PcI by the external detection methods


Pcl: pulmonary clearance; PCD: primary ciliary dyskinesia, mean ±(sD).

### S. GROTH, M. PEDERSEN

|                       | •   |            |              |              | 510 mm   | BOU       |                 | TOOLD         | - /* >      |
|-----------------------|-----|------------|--------------|--------------|--|-----------|-----------------|---------------|-------------|
| Normal<br>individuals | Sex | Age<br>yrs | Height<br>cm | Weight<br>kg | <sup>51</sup> Cr - EDTA<br>ml·min <sup>-1</sup><br>clearance | ECV<br>ml | ī(ECV+L)<br>min | ī(ECV)<br>min | ī(L)<br>min |
|                       |     |            |              | -            |  |           | 177             | 140           |             |
| 1                     | M   | 22         | 171          | 70           | 96   | 14208     | 477             | 148           | 329         |
| 2                     | Μ   | 18         | 183          | 77           | 89   | 15219     | 623             | 171           | 452         |
| 3                     | M   | 20         | 180          | 68           | 84   | 17976     | 632             | 214           | 418         |
| 4                     | F   | 27         | 166          | 50           | 79   | 12640     | 463             | 160           | 303         |
| 5                     | F   | 27         | 170          | 65           | 70   | 10570     | 492             | 151           | 341         |
| 6                     | М   | 25         | 176          | 66           | 101  | 14847     | 621             | 147           | 474         |
| 7                     | M   | 24         | 183          | 68           | 119  | 16184     | 389             | 136           | 253         |
| 8                     | M   | 23         | 171          | 60           | 103  | 15141     | 776             | 147           | 629         |
| 9                     | М   | 19         | 188          | 74           | 83   | 21165     | 386             | 255           | 131         |
| x                     |     | 23         | 176          | 66           | 92   | 15328     | 540             | 170           | 370         |
| D                     |     | 3.3        | 7.4          | 7.9          | 14.8   | 3025      | 130.5           | 39.2          | 143.5       |
| PCD patients          | 5   |            |              |              |  |           |                 |               |             |
| 1                     | F   | 24         | 160          | 50           | 91   | 8463      | 619             | 93            | 526         |
| 2                     | M   | 44         | 167          | 69           | 45   | 14040     | 966             | 312           | 654         |
| 3                     | F   | 23         | 161          | 83           | 78   | 15990     | 1318            | 205           | 1113        |
| 4                     | M   | 17         | 173          | 63           | 104  | 11336     | 1151            | 109           | 1042        |
| 5                     | F   | 36         | 173          | 55           | 85   | 11475     | 941             | 135           | 806         |
| 6                     | Μ   | 14         | 165          | 52           | 117  | 14742     | 844             | 126           | 718         |
| 7                     | M   | 20         | 185          | 82           | 150  | 15150     | 370             | 101           | 269         |
| 8                     | F   | 12         | 148          | 42           | 79   | 9717      | 628             | 123           | 405         |
| 9                     | F   | 30         | 176          | 60           | 110  | 16060     | 600             | 146           | 454         |
| 10                    | F   | 15         | 165          | 53           | 101  | 12524     | 530             | 124           | 406         |
| 1                     | F   | 30         | 163          | 53           | 90   | 14580     | 567             | 162           | 405         |
| 12                    | F   | 17         | 165          | 54           | 91   | 12467     | 551             | 137           | 414         |
| 13                    | F   | 31         | 167          | 63           | 130  | 14300     | 622             | 110           | 512         |
| 14                    | F   | 34         | 162          | 56           | 78   | 8970      | 689             | 115           | 574         |
| ā                     |     | 25         | 166          | 60           | 96   | 12844     | 743             | 143           | 593         |
| D                     |     | 9.6        | 8.6          | 11.7         | 25.6   | 2543      | 265.3           | 56.3          | 249.6       |

Table 3. - Anthropometric data; results of the determination of PcI by the plasma sample method

ECV: extracellular volume;  $\bar{t}(ECV+L)$ : mean transit time (t) for the transport of <sup>99mr</sup>Tc-DTPA from the lungs to the kidneys;  $\bar{t}(ECV)$ :  $\bar{t}$  for the transport of <sup>99mr</sup>Tc-DTPA through the ECV;  $\bar{t}(L)$ :  $\bar{t}$  for the transport of <sup>99mr</sup>Tc-DTPA across the alveolar capillary membrane.







Fig. 3. – A comparison between the individual  $FEV_1/VC$  and transit time,  $\overline{t}(L)$ , values of the normal individuals (•) and the patients PCD (O).



#### Discussion

The results of this study show that patients with primary ciliary dyskinesia (PCD) have a decreased overall pulmonary clearance (Pcl) of aerosolized <sup>99m</sup>Tc-DTPA.

It has recently been shown that DTPA is firmly bound to mucus [13]. This is consistent with the results of this study of regional Pcl, where we found a slower clearance rate in the central parts of the lungs than in the periphery of the control individuals and a similar trend in the patients with PCD. But does the pattern of aerosol deposition also explain the results of the difference in overall Pcl between the two groups? We did find an increased central deposition of the aerosol in the patients with PCD as is usually the case when patients with obstructive lung disease are studied [14]. The increased aerosol deposition in the airways probably also includes the small airways. If, in the transition between the mucus and the non-mucus lined airways, the mucous layer is so thin that DTPA may after all diffuse through it during the examination period, this may affect both the overall Pcl as measured by the plasma sample method and the initial Pcl of the lung periphery as measured by the gamma camera method. The same might be the case if in patients with PCD there should be an isolated defect of the airway epithelium permeability. There was, however, no correlation between the mean transit time (t(L)) for the transport of 99m Tc-DTPA across the alveolar capillary membrane as measured by plasma samples and the degree of air-flow limitation. In an earlier study of patients with obstructive lung disease, HUCHON et al. [15] were not able to demonstrate any change in Pcl either. The pattern of deposition is, therefore, not likely to be the only explanation of our results.

The main pathway of DTPA from the lungs to the blood is generally thought to be via the tight junctions between alveolar cells. DTPA is a hydrophilic molecule with a diameter of about 0.5 nm [16]. The equivalent pore radius of the tight junctions between alveolar cells has been estimated to be 0.8-1.0 nm [17]. It has been suggested that the diameter of the tight junction should yield passively to stretch [18]. Animal studies have shown that *i.v.* injection of olein induces an immediate increase in Pcl as measured by the external detection method [19]. This observation is difficult to explain by a concept of a single, passively regulated pore size between alveolar cells as the only limiting factor in the transport of <sup>99m</sup>Tc-DTPA from the lungs to the blood.

In most conditions the first part of the externally derived time activity curve seems to be well defined by a monoexponential fit. But in adult respiratory distress syndrome (ARDS) [20], where the clearance rate is very fast, the time activity curve is better defined by a biexponential fit. The physiological significance of two curve components is unclear, but does indicate that it is probably too simplified to consider a single size of the lumen of the tight junctions as the only limiting factor in the transport of <sup>99m</sup>Tc-DTPA from the lungs to the blood. Individuals with respiratory distress syndromes are severely deficient of alveolar surfactant. Smokers also have reduced production of surfactant [21] and a fast <sup>99m</sup>Tc-DTPA clearance rate [22]. Surfactant lining may, therefore, be associated with alveolar epithelial permeability. In fact WOLLMER *et al.* [2] found an increased pulmonary permeability of surfactant depleted rat lungs and suggested that surfactant may constitute a limiting factor in pulmonary clearance of <sup>99m</sup>Tc-DTPA. The externally detected Pcl values of this study, being less than  $15x10^{-3}$ ·min<sup>-1</sup> agree with previous observations in non-smokers. They are also in line with a possible association between surfactant and pulmonary permeability, since the patients with PCD could be expected to have decreased alveolar clearance of surfactant.

However, it is not obvious why surfactant should constitute a limiting factor. GUYTON *et al.* [23] have suggested the existence of a mechanism in which fluid filters out of the alveolar septum and then moves along the septal surface to the alveolar corners and apices where it is absorbed back into the interstitium through an epithelium that may be specialized for absorption. The experimental observation that fits with the existence of such a mechanism is the observation that when fluid containing dyes is instilled into the alveoli it moves almost instantly to the corners and there disappears into the junctional interstitium. If the reduced bronchial clearance of surfactant in Pcl is associated with an impaired alveolar wash mechanism, this may explain the decreased Pcl in patients with PCD.

Moreover, according to Fick's first law of diffusion, pulmonary clearance of <sup>99m</sup>Tc-DTPA would be expected to be proportional to PS/V [24], where P is the permeability, S is the surface area of the lung membrane, andV is the volume of fluid lining the lungs. If a consequence of a reduced alveolar clearance of surfactant is an overall increase in alveolar lining fluid, this would be consistent with a decreased Pcl.

On the other hand, in adult respiratory distress syndrome (ARDS) there is a pulmonary oedema and a severe increase in V, but also an increased Pcl. This, however, does not necessarily invalidate the possibility of a high V and a low Pcl since, as suggested by MASON *et al.* [25], in ARDS the alveolar flooding is so severe that the <sup>99m</sup>Tc-DTPA aerosol may not penetrate to the alveoli. It is probably deposited on extremely leaky terminal airways.

Pcl is increased during positive end expiratory pressure (PEEP) [26] and at high lung volumes *i.e.* when S is large [17, 27]. The TLC and VC of the PCD patients were quite low and despite the fact that eight of the patients had an obstructive lung disease the average RV/TLC was not increased (table 1). A decreased S of the PCD patients may therefore also explain the difference in Pcl between the groups.

In conclusion, patients with PCD may have reduced Pcl in comparison with normal individuals. The reason for this is unclear and several mechanisms may be involved. Reduced bronchial clearance of surfactant in PCD may be associated with an increased alveolar lining fluid volume and/or an impaired movement of <sup>99m</sup>Tc-DTPA along the alveolar septa to the bronchoalveolar junction, where the epithelium may be more specialized for absorption. In addition, the patients with PCD had small lung volumes, which in itself may theoretically be associated with reduced Pcl values.

#### References

1. Rinderknecht J, Krauthammer M, Uszler JM, Taplin G, Effros RM. – Solute transfer across the alveolar epithelial capillary membrane in pulmonary fibrosis. Am Rev Respir Dis, 1977, 115, 156.

2. Wollmer P, Evander E, Jonson B, Lachmann B. – Pulmonary clearance of inhaled <sup>99m</sup>Tc-DTPA: effect of surfactant depletion in rabbits. *Clin Physiol*, 1986, 6, 85–89.

3. Sleigh MA. – Primary ciliary dyskinesia. Lancet, 1981, 2, 476.

4. Groth S, Lassen NA, Rossing N. – Determination of the mean transit time for the transport of aerosolized <sup>99m</sup>Tc-DTPA across the pulmonary epithelial membrane. A plasma sample method. *Clin Physiol*, 1988, 8, 93–103.

5. Andersen J, Proctor DF. – Measurement of nasal mucociliary clearance. Eur J Respir Dis, 1983, 64, (Suppl. 127), 37-40.

6. Pedersen M. – Specific types of abnormal ciliary motility in Kartagener's syndrome and analogous respiratory disorders. *Eur J Respir Dis*, 1983, 64, (Suppl. 127), 78–90.

7. Nielsen MH, Pedersen M, Christensen B, Mygind N. – Blind quantitative electron microscopy of cilia from patients with primary ciliary dyskinesia and from normal subjects. *Eur J Respir Dis*, 1983, 64 (Suppl. 127), 19–30.

8. Cotes JE, Hall AM. – The transfer factor for the lung; normal values in adults. *In:* Normal values for Respiration Function in Man. P. Arcangelis ed., Pan Minerva Medica, Torino, 1970.

9. Groth S, Dirksen A, Dirksen H, Rossing N. – Intraindividual variation and effect of learning in lung function examinations. A population study. *Bull Eur Physiopathol Respir*, 1986, 22, 35–42.

10. Cotes JE. - In: Lung Function (Assessment and Application in Medicine). Blackwell, 1970, pp. 340.

11. Pearl W, Lassen NA. - In: Tracer Kinetic Methods in Medical Physiology. Raven Press, 1979, pp. 1-189.

12. Sapirstein LA, Vidt DG, Mande MJ, Hannseh G. – Volumes of distribution and clearance of intravenously injected creatinine in the dog. Am J Physiol, 1955, 181, 330–334.

13. Cheema M, Groth S, Marriott C. – Binding and diffusion characteristics of <sup>14</sup>C-EDTA and <sup>99m</sup>Tc-DTPA in purified respiratory tract mucus glycoprotein from chronic bronchitic subjects. *Thorax*, 1988, 43, 669–673..

14. Taplin GV, Chopra SK. – Inhalation lung imaging with radioactive aerosols and gases. *In:* Progress in Nuclear Medicine, Vol. 5. M. Guter ed., S. Karger, Basel. 1978, pp. 119–143.

15. Huchon GJ, Russell JA, Barritault LG, Lipavsky A, Murray JF. – Chronic air-flow limitation does not increase respiratory epithelial permeability assessed by aerosolized solute, but smoking does. Am Rev Respir Dis, 1984, 130, 457–460.

16. Jones JG. – Clearance of inhaled particles from the alveoli. *In:* Aerosols and the Lung. S.W. Clarke and D. Pavia eds, Butterworths, 1984, pp. 170–198.

17. Taylor A, Gaar K. - Estimation of equivalent pore radie

of pulmonary capillary and alveolar membranes. Am J Physiol, 1970, 218(4), 1133-1140.

18. Marks JD, Luce JM, Lazar NM, Wu JN-S, Lipavsky A, Murray JF. – Effect of increases in lung volume on clearance of aerosolized solute from human lungs. *J Appl Physiol*, 1985, 59 (Suppl. 4), 1242–1248.

19. Jones JG, Minty BD, Beeley JM, Royston D, Crow J, Grossman RF. – Pulmonary epithelial permeability is immediately increased after embolisation with oleic acid but not with neutral fat. *Thorax*, 1982, 37, 169–174.

20. Royston D, Minty B, Lockwood G, Jones JG. – Alveolar epithelial permeability (Kep) and pulmonary oedema in man. Br J Anaesth, 1983, 55, 246.

Finley T, Ladman A. - Low yield of pulmonary surfactant in cigarette smokers. N Engl J Med, 1972, 286, 223-227.
Jones JG, Lawler P, Crawley JCW, Minty BD, Hulands C, Veall N. - Increased alveolar epithelial permeability in cigarette smokers. Lancet, 1980, 1, 66-68.

23. Guyton AC, Moffatt DS, Adair TH. – Role of alveolar surface tension in transepithelial movement of fluid. In: Pulmonary Surfactant. B. Robertson, L.M.G Van Galde and J.J. Batenburg eds, Elsevier, 1984, pp. 171–185.

24. Effros RM, Mason G. - Measurement of pulmonary epithelial permeability in vivo. Am Rev Respir Dis, 1983, 127, \$59-\$65.

 Mason GR, Uszler JM, Effros RM, Reid E. – Rapidly reversible attenuations of pulmonary epithelial permeability induced by smoking. *Chest*, 1983, 83, 6–11.
Rinderknecht J, Shapiro L, Krauthammer M, Taplin G,

26. Rinderknecht J, Shapiro L, Krauthammer M, Taplin G, Wasserman K, Effros RM. – Accelerated clearance of small solutes from the lungs in interstitial lung disease. *Am Rev Respir Dis*, 1980, 121, 105–117.

27. Meignan M, Rosso J, Robert R. – Lung epithelial permeability to aerosolized solutes: relation to position. J Appl Physiol, 1987, 62, (Suppl. 3), 902–911.

Perméabilité pulmonaire dans la dyskinésie ciliaire primitive. S. Groth, M. Pedersen.

RÉSUMÉ: La clearance pulmonaire du 99mTcDTPA administré en aérosol, a été étudiée chez 14 patients atteints de dyskinésie ciliaire primitive (PCD) (âge moyen 23.5 ans, extrêmes 12-44 ans) et chez 9 individus normaux (âge moyen 23 ans, extrêmes 18-27 ans). Aucun n'avait jamais fumé. La clearance pulmonaire régionale a été étudiée pour des régions centrales et périphériques du poumon arbitrairement définies grâce à une méthode à la gamma caméra, tandis que la clearance pulmonaire totale a été étudiée par échantillonnage du plasma. Les patients atteints de dyskinésie ciliaire primitive avaient une clearance pulmonaire totale réduite par comparaison avec les individus normaux (p<0.05), ainsi que des valeurs significativement plus basses de la CPT, de la CV, du VEMS et du rapport VEMS/CV (p<0.05). Il n'y avait pas de corrélation entre la clearance pulmonaire et le rapport VEMS/CV. On conclut que la diminution de la clearance pulmonaire chez les patients atteints de dyskinésie ciliaire primitive, pourrait être en rapport avec leurs petits volumes pulmonaires. En outre, la diminution de la clearance bronchique du surfactant dans les dyskinésies pulmonaires primitives, pourrait être associée à une augmentation du volume de liquide de recouvrement alvéolaire et/ou avec un déplacement diminué du 99mTc-DTPA le long des septa alvéolaires vers la jonction broncho-alvéolaire où l'épithélium pourrait être plus spécialisé dans l'absorption.

Eur Respir J, 1989, 2, 64-70.